GlassScriptPhysician profile
Sylvia Klineova
NPI 1053572859
$228,847.68
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $18K · 2021: $29K · 2022: $16K · 2023: $30K · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $6,007 · Honoraria: $5,500 · Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,105.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,426.00 |
| Travel and Lodging | $6,006.54 |
| Honoraria | $5,500.00 |
| Food and Beverage | $2,153.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $133,764.40 | 2019-2025 | Tysabri, Plegridy, Vumerity |
| Alexion Pharmaceuticals, INC. | $38,645.97 | 2019-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $16,989.68 | 2023-2025 | Briumvi |
| Amgen INC. | $15,827.61 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $8,021.12 | 2022-2025 | |
| Emd Serono, INC. | $5,930.00 | 2022-2023 | Evobrutinib |
| Horizon Therapeutics Plc | $5,875.46 | 2023 | Uplizna |
| Greenwich Biosciences, INC. | $2,857.50 | 2021 | |
| Genentech, INC. | $850.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $85.94 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Klineova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.